11th week of 2021 patent applcation highlights part 25 |
Patent application number | Title | Published |
20210078960 | CRYSTAL AND SALT OF 4-(NAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOLE COMPOUND AND PREPARATION METHOD THEREFOR - Disclosed are a crystal of a 4-(naphthalene-1-yl)-4H-1,2,4-triazole compound (1) and a preparation method therefor, also comprised are applications of the crystal in preparing a medicament for treating an abnormal uric acid level-related disease. | 2021-03-18 |
20210078961 | TRIAZINE COMPOUND AND USE THEREOF - The present invention relates to a triazine compound and a use thereof. Specifically, the amphipathic triazine compound according to the present invention has a strong anti-bacterial effect and anti-inflammatory effect, while being excellently effective for preventing, alleviating, or treating an allergy. Also, the triazine compound according to the present invention is expected to be usefully utilized as a compound for external application on the skin, which is not toxic and can be safely used on the skin. | 2021-03-18 |
20210078962 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE - Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. | 2021-03-18 |
20210078963 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE - Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases. | 2021-03-18 |
20210078964 | PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF - The present disclosure provides processes for the production of 2-5-furandicarboxylic acid (FDCA) and intermediates thereof by the chemocatalytic conversion of a furanic oxidation substrate. The present disclosure further provides processes for preparing derivatives of FDCA and FDCA-based polymers. In addition, the present disclosure provides crystalline preparations of FDCA, as well as processes for making the same. | 2021-03-18 |
20210078965 | METHOD OF PRODUCING EPD AND ANALOGUES THEREOF - The present invention is directed to methods for the preparation of | 2021-03-18 |
20210078966 | PROCESSES FOR CONVERSION OF BIOLOGICALLY DERIVED MEVALONIC ACID - A process is provided for converting mevalonic acid into various useful products and derivatives. More particularly, the process comprises reacting mevalonic acid, or a solution comprising mevalonic acid, in the presence of a solid catalyst at an elevated temperature and pressure to thereby form various biobased products. The process may also comprise: (a) providing a microbial organism that expresses a biosynthetic mevalonic acid pathway; (b) growing the microbial organism in fermentation medium comprising suitable carbon substrates, whereby biobased mevalonic acid is produced; and (c) reacting the biobased mevalonic acid in the presence of a solid catalyst at an elevated temperature and pressure to yield various biobased products. | 2021-03-18 |
20210078967 | Acetylation of cannabinoids using sulfuric acid catalyst - A process for producing THC-O-acetate using a succession of distillation, salting-out assisted liquid-liquid extractions (SALLEs), and solvent recovery techniques. Tetrahydrocannabinol (THC) in | 2021-03-18 |
20210078968 | Purification of Cannabinoids From Crude Cannabis Oil - The present disclosure is generally directed to methods for purifying cannabinoids from | 2021-03-18 |
20210078969 | Nrf2 Activating Compounds and Uses Thereof - Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2021-03-18 |
20210078970 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER - There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers. | 2021-03-18 |
20210078971 | ARYL HETEROCYCLIC PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS - The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases. | 2021-03-18 |
20210078972 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF - The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the present invention is effective in inhibiting the action of AXL protein kinase and can inhibit proliferation, migration, and invasion of various tumor cells. Further, the quinoline or quinazoline compound of the present invention has excellent metabolic stability, high in vivo antitumor activity, low toxic side effects, and can be used for preparing a drug for preventing hyperproliferative diseases such as tumors in humans and other mammals. | 2021-03-18 |
20210078973 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS - The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: | 2021-03-18 |
20210078974 | TRIAZACYCLODODECANSULFONAMIDE ("TCD")-BASED PROTEIN SECRETION INHIBITORS - Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer. | 2021-03-18 |
20210078975 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST - The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved. | 2021-03-18 |
20210078976 | BENZAZEPINE DERIVATIVES - The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V | 2021-03-18 |
20210078977 | NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS - The application relates to a compound having Formula (I): | 2021-03-18 |
20210078978 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS - The present invention is directed to benzoimidazole compounds of the formula: | 2021-03-18 |
20210078979 | PYRAZOLE DERIVATIVES - The present invention relates to nitro-vinyl-pyrazole compounds of formula (B) | 2021-03-18 |
20210078980 | PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND - Disclosed is a process for preparing Compound 8: | 2021-03-18 |
20210078981 | COMPOUNDS AND METHODS FOR INHIBITING JAK - Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: | 2021-03-18 |
20210078982 | CYCLOHEXYL ACID PYRAZOLE AZOLES AS LPA ANTAGONISTS - The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. | 2021-03-18 |
20210078983 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. | 2021-03-18 |
20210078984 | SOLID FORMS OF (E)-3-[2-(2-THIENYL)VINYL]-1H-PYRAZOLE - The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same. | 2021-03-18 |
20210078985 | COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF - The present disclosure provides a compound of formula I or a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, wherein M is a monovalent alkali metal. The present disclosure also provides a method for preparing the compound or its pharmaceutically acceptable salt, solvate, or prodrug, and further provides a pharmaceutical composition containing the compound and its use in the preparation of a medicine, which can be used for the treatment of CCR4-mediated diseases. | 2021-03-18 |
20210078986 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION - Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over D-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed. | 2021-03-18 |
20210078987 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present disclosure relates to a novel compound and a pharmaceutical composition comprising the same. The compound according to the present disclosure has effects for activating autophagy, and thus can be valuably used for preventing or treating diseases associated with autophagy regulation. | 2021-03-18 |
20210078988 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE - Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. | 2021-03-18 |
20210078989 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME - The present disclosure relates to the field of organic electroluminescent materials and provides a heterocyclic compound and an organic electroluminescent device comprising the same. The heterocyclic compound provided by the present disclosure has a high refractive index which can reach 1.95 to 2.10. When used as a cover layer material, it can improve the transmittance of a semi-transmissive electrode, adjust the light extraction direction, and improve the light extraction efficiency. In addition, the heterocyclic compound provided by the present disclosure improves the glass transition temperature through both structure optimization. Introduction of a five-membered heterocyclic ring containing nitrogen or a six-membered heterocyclic ring containing nitrogen, benzoxazole or a benzothiazole group, allow better film-forming property and stability, such that when as used as the cover layer material of an organic electroluminescent device, it can effectively increase the service life of the device. | 2021-03-18 |
20210078990 | TYROSINE KINASE INHIBITORS - Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure | 2021-03-18 |
20210078991 | THERAPEUTIC COMPOUNDS - Compounds disclosed herein including compounds of Formula I: | 2021-03-18 |
20210078992 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME - The present specification provides a compound represented by Formula 1 and an organic light emitting device including the same. The compound is used for an organic material layer of the organic light emitting device. | 2021-03-18 |
20210078993 | A CRYSTALLINE FORM OF VALBENAZINE DITOSYLATE, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF - A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia. | 2021-03-18 |
20210078994 | MTA-Cooperative PRMT5 Inhibitors - The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. | 2021-03-18 |
20210078995 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH - The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases. | 2021-03-18 |
20210078996 | HPK1 ANTAGONISTS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders. | 2021-03-18 |
20210078997 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS - The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders. | 2021-03-18 |
20210078998 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS - The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders. | 2021-03-18 |
20210078999 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF - The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same. | 2021-03-18 |
20210079000 | PROCESS FOR PREPARATION OF GRAPIPRANT - The invention relates to process for the preparation of grapiprant and its intermediates thereof. The invention also relates to grapiprant having a purity 98% or more and compounds of Formula (A), (B), (C) and (D) in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC. The invention also relates to an amorphous form of grapiprant and process for preparation thereof. | 2021-03-18 |
20210079001 | COMPOUNDS AND METHODS FOR THE MODULATION OF AHR - Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formula: | 2021-03-18 |
20210079002 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS - Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2021-03-18 |
20210079003 | MTA-Cooperative PRMT5 Inhibitors - The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. | 2021-03-18 |
20210079004 | PROCESS FOR PREPARING BTK INHIBITORS - Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided. | 2021-03-18 |
20210079005 | COMPOUNDS - The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. | 2021-03-18 |
20210079006 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS - The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease. | 2021-03-18 |
20210079007 | MDM2 Inhibitors - A compound capable of being used as a tumor inhibitor, a preparation method therefor, and application thereof. The compound has a structure represented by general formula I; a stereoisomer, an enantiomer, a raceme, a cis/trans isomer, a tautomer, and an isotopic variant of the compound are comprised; the compound can be used separately or in combination with other drugs for treating tumors or inflammatory diseases, or for treating other disorders or diseases mediated by the activity of MDM2 and/or MDM4, and shows prominent curative activity. | 2021-03-18 |
20210079008 | Benzimidazoles and Methods of Using Same - The present disclosure is concerned with benzimidazole compounds and methods of using these compounds for the treatment of hepatitis (e.g., hepatitis C), RNA virus infections (e.g., Zika virus, dengue virus, Powassan virus, Chikungunya virus, Enterovirus, respiratory syntactical virus (RSV), Rift Valley fever, Influenza virus, Tacaribe virus, Mayaro virus, West Nile virus, yellow fever virus, and coronavirus), and disorders of uncontrolled cellular proliferation (e.g., cancer). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2021-03-18 |
20210079009 | Compounds for Coordinating with a Metal, Compositions Containing Such Compounds, and Methods of Catalyzing Reactions - A compound capable of coordinating with a metal includes a chemical structure as shown in claim | 2021-03-18 |
20210079010 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes. | 2021-03-18 |
20210079011 | ARTEMISININ-DERIVED TRIMERS AND TETRAMERS AND THEIR USE THEREOF - The present disclosure provides compositions comprising artemisinin-derived trimers and tetramers; methods of preparing these compositions; and methods for their use as medicaments. | 2021-03-18 |
20210079012 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I) | 2021-03-18 |
20210079013 | Heterobicyclic Carboxylic Acids and Salts Thereof - The present invention provides pharmaceutically acceptable salts of compounds of Formula I that are potent EP4 receptor antagonists and can be used for treating cancer or inflammatory diseases alone or in combination with antibody therapy, radiation therapy, anti-metabolite chemotherapy to a subject in need thereof. | 2021-03-18 |
20210079014 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: | 2021-03-18 |
20210079015 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B - The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV. | 2021-03-18 |
20210079016 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR - The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer. | 2021-03-18 |
20210079017 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2021-03-18 |
20210079018 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES - The present invention relates to macrocyclic indole derivatives of general formula (I): | 2021-03-18 |
20210079019 | THIAZOLIDONE SPIRO PYRIMIDINE TRIONE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF - Disclosed in the present invention are a thiazolidone spiro pyrimidine trione compound, a preparation method therefor and uses thereof, the compound having a structure represented by formula (I). In the formula, the definitions of the substituents are described in the specification and the claims. The thiazolidone spiro pyrimidine trione compound in the present invention has high in vivo and in vitro antibacterial activity, has better metabolic properties, and is obviously superior to existing compounds of the same kind. | 2021-03-18 |
20210079020 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES - The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody. | 2021-03-18 |
20210079021 | CRYSTAL FORM AND SALT FORM OF TGF-BRI INHIBITOR AND PREPARATION METHOD THEREFOR - Disclosed in the present invention are a crystal form and salt form of a TGF-βR1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers. | 2021-03-18 |
20210079022 | HETEROARYL PLASMA KALLIKREIN INHIBITORS - The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same. | 2021-03-18 |
20210079023 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS - A compound with the formula I: (I) and salts and solvates thereof, wherein: R″ is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3. | 2021-03-18 |
20210079024 | CARBAZOLE-BASED BODIPYS FOR ORGANIC ELECTROLUMINESCENT DEVICES - The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds. | 2021-03-18 |
20210079025 | PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS - Described herein is a process for preparing inorganic metal-containing films including bringing a solid substrate in contact with a compound of general formula (I) or (II) in the gaseous state | 2021-03-18 |
20210079026 | SILICON COMPOUND, PREPARATION METHOD THEREOF AND LITHIUM BATTERY - A silicon compound, a preparation method thereof, and a lithium battery are provided. The silicon compound is represented by the following Chemical formula 1: | 2021-03-18 |
20210079027 | SILANES COMPRISING OXAMIDO ESTER GROUPS - ,Oxamidoester-functional alkylalkoxysilanes are prepared in high yield by the reaction of an alkylalkoxysilane with an oxalic diester. | 2021-03-18 |
20210079028 | NOVEL ALKYLDIPHENYLMETHANE PROTECTIVE AGENT - Provided is an alkyldiphenylmethane protective agent, which can prevent solidification or insolubilization of a compound by protecting a functional group of the compound to achieve easy separation and purification after a reaction. | 2021-03-18 |
20210079029 | POLYMERISATION OF OLEFINS - A process for the polymerisation of olefins is provided, which uses a Group IV transition metal catalyst. | 2021-03-18 |
20210079030 | 3,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE-BASED PHOSPHINOOXAZOLINE LIGAND COMPOUND, PREPARATION METHOD AND USES OF THE SAME - The invention discloses a tetramethyl-7,7′-spirobiindane-based phosphinooxazoline ligand compound and its preparation method and use. The phosphinooxazoline ligand compound is a compound having a structure shown in general formula I or an enantiomer, a raceme or a diastereoisomer thereof. The phosphinooxazoline ligand obtained through a series of reaction steps using cheap and easily available 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-6,6′-diol as a starting material. The novel phosphinooxazoline ligand developed in the invention can be used to organic catalytic reactions, especially as a chiral phosphinooxazoline ligand widely used in metal-asymmetric catalytic reactions, having economical practicality and industrial application prospects. | 2021-03-18 |
20210079031 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES - The present invention concerns a compound having the following formula (I): | 2021-03-18 |
20210079032 | 1,2-PHENYLENE BRIDGED 1-INDENYL-2-INDENYL METALLOCENE COMPLEXES FOR OLEFIN POLYMERISATION - The invention relates to a metallocene complexes according to formula (I), (I) wherein R | 2021-03-18 |
20210079033 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS - There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis. | 2021-03-18 |
20210079034 | FLUORESCENT DYES AND METHODS OF USE THEREOF - Provided are methods for labeling target molecules, such as nucleic acids, with fluorescent dye compounds having the formula | 2021-03-18 |
20210079035 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS - Compounds for treating neurodegenerative disorders The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders. | 2021-03-18 |
20210079036 | COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS - The disclosure relates to chemical compositions that can include anchor molecules for chemical synthesis. GAP anchor molecules can include GAP constituents, linker constituents, and spacer constituents. Anchor molecules can be used to synthetically manufacture peptides. A novel method of solution-phase peptide synthesis is also disclosed that utilizes novel group-assisted purification protecting groups to facilitate efficient, scalable chemistry to synthetically manufacture peptides. | 2021-03-18 |
20210079037 | LIGHT-SWITCHABLE POLYPEPTIDE AND USES THEREOF - The present invention relates to a light-switchable polypeptide. In particular, the present invention relates to a polypeptide comprising a light-responsive element, wherein the configuration (i.e. the configurational state) of the light-responsive element can be switched between a trans and cis isomer by irradiating the polypeptide with (a) particular wavelength(s) of light, and wherein the switch of said configuration alters the conformation and binding activity of said polypeptide to a ligand (e.g. molecule of interest). Also, the present invention comprises using said light-switchable polypeptide for isolating and/or purifying a molecule of interest. The present invention further provides an affinity matrix, an affinity chromatography column, and an affinity chromatography apparatus comprising the light-switchable polypeptide of the invention. | 2021-03-18 |
20210079038 | METHODS FOR PRODUCING COLLAGEN - Disclosed herein are methods for efficiently isolating collagen form a collagen source. The methods are inexpensive and do not require the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the collagen produced by the methods described herein is substantially free of odor and discoloration. Still further, the collagen produced by the methods described herein is suitable to be used in cosmetics, food products, and pharmaceuticals or nutritional supplements. | 2021-03-18 |
20210079039 | COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS - Described herein are methods and compositions for the targeted delivery of therapeutic agents and imaging agents. | 2021-03-18 |
20210079040 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE AND DISC TISSUE PATHOLOGIES - An isolated polypeptide comprising a peptide selected from: i) DHX | 2021-03-18 |
20210079041 | PEPTIDE SHOWING MELANOGENESIS PROMOTING ACTIVITY AND USE THEREOF - The present invention provides a peptide exhibiting melanogenesis promoting activity. A peptide according to the present invention increases the activity and expression of tyrosinase and the expression of factors involved in melanogenesis, thereby exhibiting an outstanding effect on melanogenesis. The peptide of the present invention can be used for the prevention, alleviation, and treatment of hypomelanosis. The outstanding activity and stability stated above allow the peptide of the present invention to be very favorably applied to medicines, quasi-medicines, and cosmetics. | 2021-03-18 |
20210079042 | PEPTIDE HYDROGELS AND USE THEREOF - This disclosure provides novel anionic amphiphilic β-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject. | 2021-03-18 |
20210079043 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY - The invention describes peptide ligands specific for human plasma Kallikrein. | 2021-03-18 |
20210079044 | BIS-THIOETHER STAPLED PEPTIDES AS INHIBITORS OF PRC2 FUNCTION - This disclosure describes three novel bisthioether stapled peptides as allosteric inhibitors of Polycomb Repressive Complex 2 (PRC2) catalytic function with demonstrated cell permeability, potent activity in physiological conditions, and strong antiproliferative effects on cancer cells. These inhibitors target, for the first time, two protein interfaces in PRC2 that are crucial for its proper assembling and thus for its histone methyltransferase activity. | 2021-03-18 |
20210079045 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2021-03-18 |
20210079046 | NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASE - The disclosure is directed to compounds and methods for preparing purified macrocyclic peptide using “catch-release” methods. These methods comprise reacting a free amino group of a resin-bound linear peptide with an azide- or alkyne-functionalized cap to form a resin-bound capped linear peptide having an azide- or alkyne-functionalized cap; cleaving said capped linear peptide from the resin to form a free capped linear peptide having an azide- or alkyne-functionalized cap; reacting the free capped linear peptide having an azide-functionalized cap with an alkyne-functionalized catch resin, or reacting the free capped linear peptide having an akynyl-functionalized cap with an azide functionalized catch resin, to form a catch-resin bound capped linear peptide; reacting the catch-resin bound capped linear peptide under conditions sufficient to effect macrocyclization of the linear peptide and release of the macrocyclic peptide from the catch resin. | 2021-03-18 |
20210079047 | PREVENTION, TREATMENT AND DIAGNOSIS OF P.GINGIVALIS INFECTION - The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of | 2021-03-18 |
20210079048 | VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA SPECIES AND STRAINS - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic | 2021-03-18 |
20210079049 | Engineered Biofilms - Engineered living glues made by bacteria biofilms integrate natural marine adhesive proteins and electrostatic interactions into bacterial biofilm components such as amyloid protein TasA, surface layer protein BslA, and exopolysaccharides. | 2021-03-18 |
20210079050 | COMPOSITIONS AND METHODS FOR DELIVERY AND EXPRESSION OF SMALL INHIBITORY PEPTIDES AND USE THEREOF - The present invention is directed to, inter alia, a chimeric polynucleotide made up of a first polynucleotide encoding a specific cell predominantly expressed protein precursor and a second polynucleotide encoding a modulating-peptide. Further provided are methods for specific delivery of small modulating peptides to specific cells. Also provided are methods for treating cell-specific-associated diseases, including but not limited to, muscular, neural, hepatic and pancreatic disease, in a subject in need thereof. | 2021-03-18 |
20210079051 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS - Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. | 2021-03-18 |
20210079052 | ANALOGUES OF VDAC1-DERlVED PEPTIDES - The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto | 2021-03-18 |
20210079053 | PRODUCTION OF NERVE GROWTH FACTOR (NGF) AND OF MUTEINS THEREOF - The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and/or reduced nociceptive activity, compared to wildtype human NGF. | 2021-03-18 |
20210079054 | PEPTIDE IMMUNOGENS OF IL-31 AND FORMULATIONS THEREOF FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS - The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Interleukin-31 (IL-31) protein for the treatment and/or prevention of a pruritic condition and/or an allergic condition, such as atopic dermatitis. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs. | 2021-03-18 |
20210079055 | SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 - Novel human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2Rβ receptor and a decreased binding capacity for IL-2Rγ | 2021-03-18 |
20210079056 | C-TYPE NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES - The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof. | 2021-03-18 |
20210079057 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS - Provided herein are T cell receptor (TCR) fusion proteins (TFPs), T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer. | 2021-03-18 |
20210079058 | HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS - Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal. | 2021-03-18 |
20210079059 | TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR - The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4). | 2021-03-18 |